Home Compare COLO-B.CO vs RMD
Stock Comparison · Industry comparison · Medical Instruments & Supplies

Coloplast A/S vs ResMed: Which Stock Looks Stronger in 2026?

ResMed holds the cleaner structural position, with the lead spread across profitability and growth. Coloplast A/S does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both profitability and growth materially support the lead. ResMed Inc. leads by 34 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Medical Instruments & Supplies

This comparison is based on industry proximity, not on functional trajectory similarity. COLO-B.CO and RMD share the same industry classification.

For a similarity-based comparison, see how Coloplast A/S and ResMed each position within their functional peer groups in AssetNext.

Peer-Relative Score
COLO-B.CO
Coloplast A/S
53
Peer-Score
Signal qualityHigh
vs
RMD
ResMed Inc.
87
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: COLO-B.CO vs RMD Profitability 57 100 Stability 56 72 Valuation 54 84 Growth 44 86 COLO-B.CO RMD
Gap Ranking
#1 Profitability +43
#2 Growth +42
#3 Valuation +30
#4 Stability +16
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for COLO-B.CO and RMD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer COLO-B.CORMD Relative valuation Structural strength

ResMed Inc. looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but ResMed Inc. still holds a clear edge.
Growth
On growth, the edge is clear — both rank well, but ResMed Inc. sits noticeably higher.
Profitability — Dominant Gap
COLO-B.CO
57
RMD
100
Gap+43in favour of RMD

The profitability lead is mainly driven by a 8.9-point operating margin advantage.

What keeps the gap from being one-sided

Coloplast A/S still looks less cycle-sensitive — that keeps the result from looking completely one-sided.

What this means for the comparison

The lead is built on both profitability and growth, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the COLO-B.CO vs RMD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-growth comparisons

Explore how COLO-B.CO and RMD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.